LIMINAL BIOSCIENCES INC (LMNL) Stock Price, Quote, News and Overview
NASDAQ:LMNL - Nasdaq - CA53272L2021 - Common Stock - Currency: USD
LMNL Quote, Performance and Key Statistics
NASDAQ:LMNL (9/25/2023, 8:00:18 PM)
8.5
+0.01 (+0.12%)
The current stock price of LMNL is 8.5 USD. In the past month the price increased by 0.9%. In the past year, price increased by 102.38%.
LMNL Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About LMNL
Company Profile
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Belleville, Ontario and currently employs 43 full-time employees. The company went IPO on 2019-07-05. The firm is focused on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic and metabolic diseases using its drug discovery platform. The firm is developing Selective G-protein coupled receptor 84 (GPR84) Antagonist and Oxo-eicosanoid receptor 1 (OXER1) Antagonist. Its GPR84 is a pro-inflammatory target primarily expressed on cells associated with the immune system and its expression levels increase significantly during periods of inflammatory stress. Inhibition of GPR84 can inhibit neutrophil and macrophage migration and reduce cytokine release. GPR84 antagonist program is at the pre-clinical-stage. The OXER1 is a G protein-coupled receptor (GPCR) that is highly selective for 5-Oxo-eicosatetraenoic acid (5-oxo-ETE), a potent human eosinophil chemo-attractant. OXER1 antagonist program is in the pre-clinical-stage.
Company Info
LIMINAL BIOSCIENCES INC
231 Dundas Street East
Belleville ONTARIO H7V 4B4 CA
CEO: Bruce Pritchard
Employees: 43
Company Website: https://liminalbiosciences.com/
Phone: 14507810115.0
LIMINAL BIOSCIENCES INC / LMNL FAQ
What is the stock price of LIMINAL BIOSCIENCES INC today?
The current stock price of LMNL is 8.5 USD. The price increased by 0.12% in the last trading session.
What is the ticker symbol for LIMINAL BIOSCIENCES INC stock?
The exchange symbol of LIMINAL BIOSCIENCES INC is LMNL and it is listed on the Nasdaq exchange.
On which exchange is LMNL stock listed?
LMNL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for LIMINAL BIOSCIENCES INC stock?
6 analysts have analysed LMNL and the average price target is 7.65 USD. This implies a price decrease of -10% is expected in the next year compared to the current price of 8.5. Check the LIMINAL BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is LIMINAL BIOSCIENCES INC worth?
LIMINAL BIOSCIENCES INC (LMNL) has a market capitalization of 19.82M USD. This makes LMNL a Nano Cap stock.
How many employees does LIMINAL BIOSCIENCES INC have?
LIMINAL BIOSCIENCES INC (LMNL) currently has 43 employees.
What are the support and resistance levels for LIMINAL BIOSCIENCES INC (LMNL) stock?
LIMINAL BIOSCIENCES INC (LMNL) has a support level at 8.47 and a resistance level at 8.51. Check the full technical report for a detailed analysis of LMNL support and resistance levels.
Should I buy LIMINAL BIOSCIENCES INC (LMNL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of LMNL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of LMNL, evaluating the profitability, health, valuation and growth aspects
- LIMINAL BIOSCIENCES INC (LMNL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- LIMINAL BIOSCIENCES INC (LMNL) Sales and EPS estimates to see what analysts future expectations are.
- LIMINAL BIOSCIENCES INC (LMNL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- LIMINAL BIOSCIENCES INC (LMNL) Insider and Institutional Ownership to learn about the owners and their transactions.
- LIMINAL BIOSCIENCES INC (LMNL) Stock Chart to make your own analysis
- LIMINAL BIOSCIENCES INC (LMNL) Latest news and press-releases to stay up to date.
Does LIMINAL BIOSCIENCES INC (LMNL) stock pay dividends?
LMNL does not pay a dividend.
When does LIMINAL BIOSCIENCES INC (LMNL) report earnings?
LIMINAL BIOSCIENCES INC (LMNL) will report earnings on 2023-11-07, after the market close.
What is the Price/Earnings (PE) ratio of LIMINAL BIOSCIENCES INC (LMNL)?
The PE ratio for LIMINAL BIOSCIENCES INC (LMNL) is 77.27. This is based on the reported non-GAAP earnings per share of 0.11 and the current share price of 8.5 USD. Check the full fundamental report for a full analysis of the valuation metrics for LMNL.
LMNL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to LMNL. When comparing the yearly performance of all stocks, LMNL is one of the better performing stocks in the market, outperforming 98.13% of all stocks.
LMNL Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LMNL. LMNL may be in some trouble as it scores bad on both profitability and health.
LMNL Financial Highlights
Over the last trailing twelve months LMNL reported a non-GAAP Earnings per Share(EPS) of 0.11. The EPS decreased by -99.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 94.11% | ||
| ROA | 1.46% | ||
| ROE | 2.16% | ||
| Debt/Equity | 0.02 |
LMNL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to LMNL. The Buy consensus is the average rating of analysts ratings from 6 analysts.